Progress in Value-Based Reimbursement

Oncology drug spend is expected to increase to nearly $230 billion by 2023. One key driver of this increase is immuno-oncology drugs, which are costly but also have significantly improved the outlook of indicated diseases. Articles in this issue include research on new payment models and payer management tools that are starting to emerge in an effort to more effectively manage costs. In addition, results from a retrospective real-world study of the effectiveness of eribulin in subgroups of metastatic breast cancer (MBC) patients with poor prognostic characteristics is presented. We close this month’s issue with insights on the 2021 Oncology Care Model (OCM) evaluation report released by the Centers for Medicare & Medicaid Services (CMS) in January...